Seelos Therapeutics doses first ALS patient with SLS-005

Seelos Therapeutics announced it has dosed the first patient in an Expanded Access Program for patients with ALS who do not qualify for existing clinical trials and that the EAP will be fully funded by a grant from the NINDS under the ACT for ALS. Under this EAP, Seelos plans to initially enroll 70 patients in a 24-week, open-label study to evaluate SLS-005 in persons with ALS in parallel to its ongoing, fully enrolled, randomized double-blind placebo-controlled Phase II/III study on the HEALEY ALS Platform.